BioNexus Gene Lab Corp (BGLC) income statement
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3090% below fair value
$0.73−0.03 (-4.27%)
Close on Nov 18, 2026Market cap $2.15MP/E –Yield –
BioNexus Gene Lab Corp income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 12.3%
- Operating margin
- -81.8%
- Net margin
- -82.4%
- Return on equity, FY2025
- -35.2%
Financial strength
- Current ratio
- 6.08
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 151.6%
Valuation
- P/E ratio
- –
- Price to sales
- 0.69
- Price to book
- 0.28
- Dividend yield
- –
See a number that looks wrong?